683 Capital Management’s ProKidney PROK Stock Holding History

683 Capital Management’s Portfolio PROK Stock Details PROK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-500,000	Closed	-$4.97M	–	248
2022 Q2	$4.97M	Hold	500,000	–	–	0.35%	71
2022 Q1	$4.95M	Buy	+500,000	New	+$4.93M	0.27%	79

Other funds holding PROK

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

MCM

Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

683 Capital Management's PROK Position: Q3 2022 in Review

683 Capital Management sold out of ProKidney (PROK) in Q3 2022, closing a stake of 500,000 shares — an estimated $4.97M sold.

683 Capital Management first reported a position in PROK in Q1 2022 and held it in 2 quarters. The position peaked at $4.97M in Q2 2022. 18 funds tracked by Wall St. Rank hold PROK as of Q3 2022.

683 Capital Management reported no remaining ProKidney position as of Q3 2022 after selling out during the quarter.
683 Capital Management sold 500,000 ProKidney shares in Q3 2022, an estimated $4.97M.
683 Capital Management first reported a position in ProKidney in Q1 2022 and held it in 2 quarters.
683 Capital Management's ProKidney position peaked at $4.97M in Q2 2022.
18 funds tracked by Wall St. Rank held ProKidney as of Q3 2022.

Based on 683 Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.